Generalized metabolic bone disease in Neurofibromatosis type I
- PMID: 18289904
- PMCID: PMC2430595
- DOI: 10.1016/j.ymgme.2007.12.004
Generalized metabolic bone disease in Neurofibromatosis type I
Abstract
Skeletal abnormalities are a recognized component of Neurofibromatosis type I (NF1) but a generalized metabolic bone defect in NF1 has not been fully characterized thus far. The purpose of this study was to characterize at the densitometric, biochemical and pathological level the bone involvement in NF1 patients. Using dual energy X-ray absorptiometry (DXA) we analyzed bone status in 73 unselected NF1 subjects, 26 males and 47 females, mainly children and adolescents (mean age: 16.6 years). In a subgroup of subjects with low bone mass, we measured indices of calcium-phosphate metabolism, bone turnover, and bone density before and after vitamin D and calcium treatment. We found statistically significant and generalized reduction in bone mass with the mean lumbar bone mineral density (BMD) z-score being -1.38+/-1.05 (CI 95% -1.62 to -1.13), and whole body bone mineral content (BMC) z-score -0.61+/-1.19 (CI 95% -0.94 to -0.29), both significantly reduced compared to normal controls (p<.001). PTH was moderately elevated and after 4 months of supplemental therapy with calcium and vitamin D, it decreased to the normal range. However, BMD z-scores did not significantly improve after 2 years of follow-up. Histological analysis of bone samples from NF1 patients revealed substantial alteration of bone microarchitecture due mainly to reduced trabecular bone. Our observations are consistent with a generalized bone metabolic defect due to loss of the function of neurofibromin. Early identification of patients with osteoporosis may permit more timely and aggressive treatments to prevent the likely substantial morbidity associated with increased fracture risk later in life.
Figures




Similar articles
-
High bone turnover and accumulation of osteoid in patients with neurofibromatosis 1.Osteoporos Int. 2010 Jan;21(1):119-27. doi: 10.1007/s00198-009-0933-y. Epub 2009 May 5. Osteoporos Int. 2010. PMID: 19415373
-
Bone mineral density and bone metabolic markers' status in children with neurofibromatosis type 1.J Pediatr Endocrinol Metab. 2017 Feb 1;30(2):175-180. doi: 10.1515/jpem-2016-0092. J Pediatr Endocrinol Metab. 2017. PMID: 28125404
-
Bone health and fracture rate in individuals with neurofibromatosis 1 (NF1).J Med Genet. 2009 Apr;46(4):259-65. doi: 10.1136/jmg.2008.061895. Epub 2008 Dec 9. J Med Genet. 2009. PMID: 19066167
-
Bone Mineral Density in Neurofibromatosis Type 1: A Systematic Review and Meta-Analysis.Calcif Tissue Int. 2023 Aug;113(2):166-174. doi: 10.1007/s00223-023-01094-z. Epub 2023 May 23. Calcif Tissue Int. 2023. PMID: 37221347
-
Current Aspects on the Pathophysiology of Bone Metabolic Defects during Progression of Scoliosis in Neurofibromatosis Type 1.J Clin Med. 2022 Jan 15;11(2):444. doi: 10.3390/jcm11020444. J Clin Med. 2022. PMID: 35054138 Free PMC article. Review.
Cited by
-
Non-Oncological Neuroradiological Manifestations in NF1 and Their Clinical Implications.Cancers (Basel). 2021 Apr 12;13(8):1831. doi: 10.3390/cancers13081831. Cancers (Basel). 2021. PMID: 33921292 Free PMC article. Review.
-
Overlooked Hoffa Fracture in a Patient With Neurofibromatosis-1.J Am Acad Orthop Surg Glob Res Rev. 2017 Nov 23;1(8):e060. doi: 10.5435/JAAOSGlobal-D-17-00060. eCollection 2017 Nov. J Am Acad Orthop Surg Glob Res Rev. 2017. PMID: 30211369 Free PMC article.
-
Molecular Basis of Fracture Pseudarthrosis Associated with Neurofibromatosis Type 1.J Pediatr Soc North Am. 2025 May 23;12:100202. doi: 10.1016/j.jposna.2025.100202. eCollection 2025 Aug. J Pediatr Soc North Am. 2025. PMID: 40756144 Free PMC article. Review.
-
Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966.Orphanet J Rare Dis. 2020 Feb 3;15(1):37. doi: 10.1186/s13023-020-1310-3. Orphanet J Rare Dis. 2020. PMID: 32014052 Free PMC article.
-
High bone turnover and accumulation of osteoid in patients with neurofibromatosis 1.Osteoporos Int. 2010 Jan;21(1):119-27. doi: 10.1007/s00198-009-0933-y. Epub 2009 May 5. Osteoporos Int. 2010. PMID: 19415373
References
-
- Friedman JM. Epidemiology of neurofibromatosis type 1. Am J Med Genet. 1999;89:1–6. - PubMed
-
- Carey JC, Viskochil DH. Neurofibromatosis type 1: A model condition for the study of the molecular basis of variable expressivity in human disorders. Am J Med Genet. 1999;89:7–13. - PubMed
-
- Crawford AH, Jr, Bagamery N. Osseous manifestations of neurofibromatosis in childhood. J Pediatr Orthop. 1986;6:72–88. - PubMed
-
- Riccardi VM. Von Recklinghausen neurofibromatosis. N Engl J Med. 1981;305:1617–1627. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous